Clinical trials that involve use of a new medicine require approval under Section 30 of the Medicines Act 1981. The HRC's Standing Committee on Therapeutic Trials (SCOTT) undertakes scientific assessment of applications to conduct trials and makes recommendations to the Director-General of Health on whether or not trials should be approved.

Committee members: 

Associate Professor Richard Robson - Chair
Christchurch Clinical Studies Trust
Emeritus Professor Carl Burgess
Dr Matthew Dawes
The University of Auckland, Auckland
Professor Stephen Duffull
School of Pharmacy, University of Otago, Dunedin
Professor Chris Frampton
Christchurch School of Medicine and Health Sciences
Dr Sisira Jayathissa
Hutt Valley District Health Board, Wellington
Dr Damian Pethica
Professor Paul Smith 
School of Medical Sciences, University of Otago, Dunedin
Mr Trevor Speight
Professor Ian Tucker
School of Pharmacy, University of Otago, Dunedin
Dr Chris Wynne
Christchurch Clinical Studies Trust

Ex officio members:
Dr Alexander Bolotovski
Medsafe, Ministry of Health
Professor Kathryn McPherson
Chief Executive, Health Research Council of New Zealand

Conflict of interest
The policy of the HRC is that potential conflicts of interest should be declared in the appropriate way and for any conflicts of interest to be managed in a transparent and appropriate way for the protection of the HRC, the Board and Committee members. All members of the HRC Board and HRC Committees have an obligation to disclose an interest in a matter of the HRC . A ‘matter’ includes any of the HRC’s functions to promote and fund health research and any arrangement or contract entered into for research funding.By disclosing interests members ensure that they are accountable and that the integrity and public confidence in the HRC is maintained.

SCOTT contact: Richard Robson, tel: 03 372 9477 email:

Medsafe contact: Ms Becci Slyfield, email:

Terms of Reference